SCHEMBL3392126

SCHEMBL3392126

CC1CCC(=O)C=C1CCCCCCCCCCCCCCCO

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.36
LMNA P02545 1/20 0.33
PGR P06401 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAOA P21397 1/20 0.33
TBXA2R P21731 1/20 0.33
MAPK1 P28482 1/20 0.33
AVPR2 P30518 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTR2B P41595 1/20 0.33
HTT P42858 1/20 0.33
PDE3A Q14432 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
SLC29A1 Q99808 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389359 1.00 ALOX5 (0.36) ALOX5LMNAPGRCYP3A4CYP2D6
SCHEMBL3390127 1.00 ALOX5 (0.36) ALOX5LMNAPGRCYP3A4CYP2D6
SCHEMBL3388102 1.00 ALOX5 (0.36) ALOX5LMNAPGRCYP3A4CYP2D6
SCHEMBL3390606 1.00 ALOX5 (0.36) ALOX5LMNAPGRCYP3A4CYP2D6
SCHEMBL3390843 1.00 ALOX5 (0.36) ALOX5LMNAPGRCYP3A4CYP2D6
SCHEMBL7911738 0.82 PTGER2 (0.31)
SCHEMBL13909313 0.81 CYP19A1 (0.36) ALOX5
SCHEMBL27721319 0.69
SCHEMBL27721303 0.69
SCHEMBL27721326 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368013-B1 CYCLOHEXENONE DERIVATIVE FOR TREATING DIABETIC NEUROPATHY MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
US-7838565-B2 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications MEIJI DAIRIES CORPORATION (JP) 2010-11-23 US disclosed
EP-1322748-B1 STEM CELL DIFFERENTIATION-INDUCING PROMOTER MEIJI DAIRIES CORP (JP) 2009-12-02 EP disclosed
EP-1368014-B1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA MEIJI DAIRIES CORP (JP) 2006-11-22 EP disclosed
US-6906107-B2 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria MEIJI DAIRIES CORPORATION (JP) 2005-06-14 US disclosed
US-20040132829-A1 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-07-08 US disclosed
US-20040115810-A1 Stem cell differentiation-inducing promoter MEIJI DAIRIES CORPORATION (JP) 2004-06-17 US disclosed
US-20040102527-A1 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-05-27 US disclosed
EP-1368013-A1 USE OF A CYCLOHEXENONE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DIABETIC COMPLICATIONS Meiji Dairies Corporation (JP) 2003-12-10 EP disclosed
EP-1368014-A1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA Meiji Dairies Corporation (JP) 2003-12-10 EP disclosed
EP-1322748-A2 STEM CELL DIFFERENTIATION-INDUCING PROMOTER Meiji Dairies Corporation (JP) 2003-07-02 EP disclosed
WO-2002066023-A1 USE OF A CYCLOHEXENONE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DIABETIC COMPLICATIONS MEIJI DAIRIES CORPORATION (JP) 2002-08-29 WO disclosed
WO-2002066024-A1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA MEIJI DAIRIES CORPORATION (JP) 2002-08-29 WO disclosed
WO-2002029014-A2 STEM CELL DIFFERENTIATION-INDUCING PROMOTER MEIJI DAIRIES CORPORATION (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132829-A1 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria ADH1A, ADH1C, NDUFB7 ALOX5 852/4885LMNA 1761/4885PGR 4228/4885
US-20040102527-A1 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications GPR119, CYC1, CYP11B1 ALOX5 155/4885LMNA 2236/4885PGR 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.